AMERICAN ACADEMIC PUBLISHER

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206 Volume 5. No 12. December ,2025

THE METABOLIC PANDEMIC: THE GLOBAL RISE OF INSULIN RESISTANCE AND FUTURE RISKS

G'ulomova Shahrinoz Qahramon qizi

Department of Fundamental Medicine, Asia International University, Bukhara, Uzbekistan

Abstract: Insulin resistance has emerged as one of the most significant global health threats of the 21st century. Often asymptomatic for years, it serves as the metabolic foundation for type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), cardiovascular disease, and multiple cancers. Despite its clinical and socioeconomic burden, insulin resistance remains underdiagnosed and underestimated. This review synthesizes recent epidemiological trends, pathophysiological mechanisms, environmental contributors, and long-term global risks, while highlighting urgent priorities for prevention and policy intervention.

Keywords: Insulin resistance, metabolic pandemic, global health, type 2 diabetes, metabolic syndrome, obesity, adipose tissue dysfunction, NAFLD, endocrine-disrupting chemicals, lifestyle factors, epidemiology, cardiovascular risk, hyperinsulinemia, public health policy, metabolic disorders.

Introduction

Insulin resistance (IR) represents a diminished cellular response to insulin, particularly in skeletal muscle, adipose tissue, and liver. Historically considered a precursor to diabetes, IR is now recognized as a central driver of a cluster of metabolic abnormalities collectively termed metabolic dysfunction-associated conditions.

Recent estimates suggest that over 1.5 billion people worldwide are affected by clinically significant insulin resistance, with prevalence projected to rise sharply by 2050. The phenomenon has been referred to as a "metabolic pandemic," reflecting rapid global expansion driven by urbanization, dietary shifts, sedentary lifestyles, and environmental stressors.

Global Epidemiology

Geographic distribution

Asia shows the fastest-growing rates despite lower BMI thresholds, due to high visceral adiposity prevalence.

Middle Eastern and North African regions demonstrate some of the highest global rates of metabolic syndrome.

North America and Europe exhibit longstanding but increasingly plateaued trends, though childhood IR is rising.

Sub-Saharan Africa is experiencing accelerated growth linked to economic transition and urbanization.

Age and gender patterns

IR is now detected even in children under 10, correlating with global childhood obesity.

Women disproportionately experience IR secondary to PCOS and pregnancy-related metabolic shifts.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 12. December ,2025

Pathophysiology of Insulin Resistance

IR results from a complex interaction between molecular, cellular, and systemic mechanisms:

Cellular mechanisms

Impaired insulin receptor signaling, specifically IRS-1/PI3K/Akt pathway dysfunction.

Accumulation of lipotoxic intermediates (ceramides, diacylglycerols) disrupting phosphorylation cascades.

Mitochondrial dysfunction leading to reduced fatty acid oxidation.

Adipose tissue dysfunction

Chronic low-grade inflammation driven by macrophage infiltration.

Dysregulated secretion of adipokines such as decreased adiponectin and increased leptin.

Hepatic contributions

Excessive hepatic gluconeogenesis.

Early development of NAFLD, now the world's most common chronic liver disease.

Microbiome alterations

Emerging evidence links gut dysbiosis, intestinal permeability, and endotoxemia to systemic IR.

Environmental and Lifestyle Drivers

Nutrition transition

Global adoption of Western-style diets high in refined carbohydrates, saturated fats, and ultraprocessed foods fuels IR progression.

Sedentary behavior

Physical inactivity reduces GLUT4-mediated glucose uptake in muscle, hastening IR.

Sleep disturbance and stress

Chronic cortisol elevation, circadian disruption, and sleep deprivation contribute to metabolic dysfunction.

Endocrine-disrupting chemicals (EDCs)

Widespread exposure to BPA, phthalates, PFAS, and pesticides modulates insulin sensitivity through receptor interference and epigenetic effects.

Long-Term Global Risks

Without coordinated intervention, the rise in IR is expected to:

Increase global diabetes burden

T2DM prevalence is predicted to reach over 1.3 billion by 2050, largely driven by undetected IR.

Accelerate cardiovascular mortality

IR is a major driver of hypertension, dyslipidemia, atherosclerosis, and stroke.

Overwhelm healthcare systems

Direct and indirect costs of T2DM and metabolic diseases may exceed $2–3 trillion annually by 2040.

Reduce global workforce productivity

Higher disease burden among working-age adults impacts national economic growth.

Increase cancer incidence

IR is linked with breast, colorectal, endometrial, pancreatic, and liver cancers via hyperinsulinemia and IGF-1 dysregulation.

Strategies for Prevention and Intervention

Individual-level approaches

Structured exercise programs targeting ≥150 min/week.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 12. December ,2025

Low-glycemic, high-fiber dietary patterns: Mediterranean, DASH, and plant-forward diets.
Weight reduction of 5–10% can dramatically reverse IR.
Medical interventions Metformin, GLP-1 receptor agonists, SGLT2 inhibitors, and emerging dual agonists show promising outcomes. Early screening for high-risk groups (PCOS, NAFLD, gestational diabetes). Public health and policy solutions Taxation of ultraprocessed foods and sugar-sweetened beverages.Urban planning to encourage physical activity. Regulation of endocrine-disrupting chemicals. Mass education campaigns on metabolic health.

Future Directions

Research priorities include:
Biomarkers for early detection of IR before metabolic damage occurs.
Precision medicine approaches based on genetics, microbiome, and metabolomics.
Long-term effects of GLP-1 and twincretin agents on metabolic aging.
Large-scale interventions in low- and middle-income countries, where prevalence is rising fastest.

Conclusion

Insulin resistance represents a silent but rapidly expanding global health emergency. Its role as the metabolic foundation for multiple chronic diseases demands urgent international attention. Without coordinated public health strategies, the “metabolic pandemic” will impose unprecedented medical, economic, and societal burdens. Early detection, lifestyle interventions, policy changes, and innovation in metabolic therapeutics remain crucial to reversing current trends.

References:

1. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 2021;44(9):2399–2411.
2. International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels: IDF; 2021.
3. Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
4. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2019;148(5):852–871.
5. Zimmet P, Magliano D, Herman W, Shaw J. Diabetes: A 21st century challenge. Lancet Diabetes Endocrinol. 2014;2(1):56–64.
6. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2022;75(4):1048–1061.
7. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–846.
8. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133–2223.
9. Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes. Lancet. 2018;391(10120):541–551.
10. Malik VS, Li Y, Pan A, et al. Long-term consumption of sugar-sweetened and artificially sweetened beverages and risk of mortality. Circulation. 2019;139(18):2113–2125.
11. Heindel JJ, Blumberg B, Schug TT. Endocrine disruptors and obesity. Nat Rev Endocrinol. 2022;18:344–357.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 12. December ,2025

12. Reaven GM. Insulin resistance: the hallmark of metabolic syndrome. Clin Chem. 2011;57(5):633–638.
13. WHO. Global Report on Diabetes. Geneva: World Health Organization; 2021.
14. Zeng Q, Dong S, Sun X, et al. Visceral adiposity as a new phenotypic marker of insulin resistance. Nutr Metab Cardiovasc Dis. 2020;30(8):1378–1384.
15. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756.